What it sells
Graph Safety automates pharmacovigilance intake, case processing and aggregate reporting for pharma and biotech safety teams.
Business model breakdown
Buyer: who owns the budget?
UnverifiedHead of Pharmacovigilance / Drug Safety at pharma, biotech and CROs.
Trigger: what makes them buy now?
UnverifiedRising case volumes and manual case-processing cost, plus regulatory pressure for inspection-ready, auditable safety operations.
Workflow: what inputs become what output?
Ingests safety cases from email, PDF, XML, APIs, literature and partner feeds, extracts patient/drug/event data, codes with MedDRA, dedupes, builds submission-ready cases, then generates E2B(R3) regulatory reports (report, signal detection, assure, comply modules rolling out Aug 2026 to Jan 2027).
Economics: what it saves and how it charges
Software platform; site claims 90% reduction in effort, 92% faster processing and 66% cost savings in pharmacovigilance operations.
Distribution: how it reaches customers
Demo-led sales ('Talk to our team', 'See it in action'); offices in Pleasanton CA and Hyderabad.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| 2026-09-10 | Series A | $13.3M | Insight Partners (lead), Bessemer Venture Partners | entrackr.com |
| 2026-08-13 | Series A | KRW 17B | K2 Investment Partners (lead), A.ventures, GY Investment (per Daum snippets) | news.google.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-13.